StrataStem is an innovative spin-out biotech working at the forefront of Alzheimer's disease (AD) research and is developing intelligent phenotype-genotype (iPG) drug screening platforms to identify appropriate therapeutics for AD. We use induced Pluripotent Stem Cells (iPSCs) derived from AD patients to rapidly isolate neural progenitor cells, using our patented technology, to create Alzheimer’s disease in a dish cell models.
Diseases we are modelling with our iPG drug screening technology include familial and sporadic (late-onset) dementia, schizophrenia, epilepsy and other difficult to treat neurological conditions. We work with industrial pharmaceutical collaborators to test repurposed drug libraries, identify patient cohorts for inclusion within clinical trials and use our novel humanized network modelling technology to identify new disease targets and biomarkers. Our disruptive technology allows us to target the right patient with the right drug at the right time and will pave the way for optimal patient stratification for a range of difficult to treat neurological diseases/disorders and orphan diseases.